Back to search

Article

NTBC dosing and outcomes in hereditary tyrosinemia type 1: insights from a representative human model and 99 patients

2025-10-07

Abstract excerpt

Hereditary tyrosinemia type 1 (HT1) is a rare and severe metabolic liver disorder caused by fumarylacetoacetate hydrolase (FAH) deficiency. The optimal dose and long-term effects of the only available treatment, nitisinone (NTBC), remain unclear due to the absence of clinical trial data. Here, we generated a representative human in vitro model of HT1 using iPSC-derived hepatocytes, which faithfully recapitulated k...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5ba801fe-d269-5550-8266-43e289e50593
DOI
10.1101/2025.10.06.680797
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
NTBC dosing and outcomes in hereditary tyrosinemia type 1: insights from a representative human model and 99 patientsDOI 10.1101/2025.10.06.680797
Select a neighboring publication to make it the new centre.